BRIA-ABC: Bria-IMT plus Immunotherapy for Patients with Pre-Treated Metastatic Breast Cancer
Condition: Breast Cancer
Sponsor: BriaCell Therapeutics Corporation
Full Title
BC-IMT-04: Randomized, Open-label Study of the Bria-IMT Regimen and Check Point Inhibitor vs Physician’s Choice in Advanced Metastatic Breast Cancer
Study Treatment
GM-CSF-secreting breast cancer vaccine SV-BR-1-GM in combination with anti-PD1 immunotherapy retifanlimab-dlwr
Eligibility/Info
Eligible patients will have one of the following prior treatment histories:
- HR+/HER2-: Previously treated with at least 2 prior chemotherapy or targeted therapy regimens
- HER2+: Previously treated with at least 3 treatment regimens including 2 anti-HER2 therapies
- TNBC: Exhausted all standard of care therapies known to confer clinical benefit
- HER2-Low: Previously treated with at least 1 anti-HER2 therapy in addition to the appropriate HR status therapies
- Actionable Mutation: Patients with an actionable mutation must have been treated with appropriate targeted therapy
Contact
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.
